Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
SERES THERAPEUTICS INC (MCRB) Stock Price & Overview
NASDAQ:MCRB • US81750R2013
Current stock price
7.05 USD
-0.04 (-0.56%)
At close:
7.05 USD
0 (0%)
After Hours:
The current stock price of MCRB is 7.05 USD. Today MCRB is down by -0.56%. In the past month the price decreased by -20.52%. In the past year, price decreased by -26.79%.
MCRB Key Statistics
52-Week Range6.53 - 29.98
Current MCRB stock price positioned within its 52-week range.
1-Month Range6.5601 - 9.335
Current MCRB stock price positioned within its 1-month range.
- Market Cap
- 67.61M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.07
- Dividend Yield
- N/A
MCRB Stock Performance
Today
-0.56%
1 Week
-16.47%
1 Month
-20.52%
3 Months
-52.75%
Longer-term
6 Months -56.21%
1 Year -26.79%
2 Years -64.42%
3 Years -92.77%
5 Years -98.31%
10 Years -98.81%
MCRB Stock Chart
MCRB Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MCRB. When comparing the yearly performance of all stocks, MCRB is a bad performer in the overall market: 92.77% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
MCRB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MCRB. The financial health of MCRB is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MCRB Earnings
On March 12, 2026 MCRB reported an EPS of -1.78 and a revenue of 438.00K. The company beat EPS expectations (17.29% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$1.78
Revenue Reported438K
EPS Surprise 17.29%
Revenue Surprise %
MCRB Forecast & Estimates
7 analysts have analysed MCRB and the average price target is 22.44 USD. This implies a price increase of 218.3% is expected in the next year compared to the current price of 7.05.
For the next year, analysts expect an EPS growth of -38.3% and a revenue growth -100% for MCRB
Analysts
Analysts82.86
Price Target22.44 (218.3%)
EPS Next Y-38.3%
Revenue Next Year-100%
MCRB Index Membership
MCRB is currently included in the following stock indexes tracked on ChartMill.
MCRB Financial Highlights
Over the last trailing twelve months MCRB reported a non-GAAP Earnings per Share(EPS) of -6.07. The EPS increased by 68.71% compared to the year before.
Income Statements
Revenue(TTM)789.00K
Net Income(TTM)5.70M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 721.93% | ||
| ROA | 4.12% | ||
| ROE | 12.88% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%11%
Sales Q2Q%N/A
EPS 1Y (TTM)68.71%
Revenue 1Y (TTM)N/A
MCRB Ownership
Ownership
Inst Owners25.66%
Shares9.59M
Float8.44M
Ins Owners0.45%
Short Float %6.93%
Short Ratio10.26
MCRB Industry Overview
MCRB operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.2%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.1
- Average Fwd P/E
- 22.4
- Average Debt/Equity
- 2.1
MCRB Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.42 | 360.632B | ||
| AMGN | AMGEN INC | 14.8 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.44 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.89 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 25.03B | ||
| INCY | INCYTE CORP | 10.85 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MCRB
Company Profile
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Company Info
IPO: 2015-06-26
SERES THERAPEUTICS INC
101 Cambridge Park Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Eric D. Shaff
Employees: 66
Phone: 16179459626
SERES THERAPEUTICS INC / MCRB FAQ
What does SERES THERAPEUTICS INC do?
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-26. The company is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
What is the current price of MCRB stock?
The current stock price of MCRB is 7.05 USD. The price decreased by -0.56% in the last trading session.
Does SERES THERAPEUTICS INC pay dividends?
MCRB does not pay a dividend.
What is the ChartMill technical and fundamental rating of MCRB stock?
MCRB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy MCRB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MCRB.
Can you provide the number of employees for SERES THERAPEUTICS INC?
SERES THERAPEUTICS INC (MCRB) currently has 66 employees.
What is SERES THERAPEUTICS INC worth?
SERES THERAPEUTICS INC (MCRB) has a market capitalization of 67.61M USD. This makes MCRB a Micro Cap stock.